DHSC gives go ahead for boys to receive HPV vaccine

DHSC gives go ahead for boys to receive HPV vaccine

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect...

Home Office gives go ahead to allow cannabis-derived products on prescription

Home Office gives go ahead to allow cannabis-derived products on prescription

July 27 2018 Certain cannabis-derived products will be reclassified as Class 2 medicinal...

New law strengthens punishment for assaulting health sector workers

New law strengthens punishment for assaulting health sector workers

July 27 2018 A new law will increase the possible sentencing of someone who commits common...

Asthma deaths levels increase by a quarter in a decade

Asthma deaths levels increase by a quarter in a decade

July 26 2018 There were 1,320 deaths due to asthma in England and Wales in 2017, the highest...

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

July 24 2018 New Health Secretary Matt Hancock has called for investment in primary care and...

  • DHSC gives go ahead for boys to receive HPV vaccine

    DHSC gives go ahead for boys to receive HPV vaccine

    Friday, 27 July 2018 16:22
  • Home Office gives go ahead to allow cannabis-derived products on prescription

    Home Office gives go ahead to allow cannabis-derived products on prescription

    Friday, 27 July 2018 16:19
  • New law strengthens punishment for assaulting health sector workers

    New law strengthens punishment for assaulting health sector workers

    Friday, 27 July 2018 16:16
  • Asthma deaths levels increase by a quarter in a decade

    Asthma deaths levels increase by a quarter in a decade

    Thursday, 26 July 2018 15:29
  • Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Tuesday, 24 July 2018 13:07

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Professional News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...